Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADREM study of insulin degludec dose adjustment after exercise in adults with type 1 diabetes
NL-OMON48464Phase 4Completed
- Sponsor
- Afdeling Interne Geneeskunde
- Start
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of insulin degludec in diabetes mellitus type 1 (T1D) (3 arms), sponsored by Afdeling Interne Geneeskunde. Primary endpoint: Time spent in nocturnal hypoglycaemia after exercise. Started Sep 2020; status: completed.
02
Drugs
insulin degludec
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON48464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48464.